NO309704B1 - Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) - Google Patents
Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) Download PDFInfo
- Publication number
- NO309704B1 NO309704B1 NO943102A NO943102A NO309704B1 NO 309704 B1 NO309704 B1 NO 309704B1 NO 943102 A NO943102 A NO 943102A NO 943102 A NO943102 A NO 943102A NO 309704 B1 NO309704 B1 NO 309704B1
- Authority
- NO
- Norway
- Prior art keywords
- fatty acids
- dic
- emulsion
- treatment
- dose
- Prior art date
Links
- 208000009190 disseminated intravascular coagulation Diseases 0.000 title claims abstract description 75
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 239000000194 fatty acid Substances 0.000 title claims description 69
- 235000014113 dietary fatty acids Nutrition 0.000 title claims description 57
- 229930195729 fatty acid Natural products 0.000 title claims description 57
- 150000004665 fatty acids Chemical class 0.000 title claims description 57
- 238000011161 development Methods 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 230000002265 prevention Effects 0.000 title claims description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000839 emulsion Substances 0.000 claims abstract description 57
- 239000003921 oil Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 16
- 230000004872 arterial blood pressure Effects 0.000 claims abstract description 13
- 210000001147 pulmonary artery Anatomy 0.000 claims abstract description 9
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 235000019198 oils Nutrition 0.000 claims description 38
- 235000021476 total parenteral nutrition Nutrition 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000011866 long-term treatment Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 14
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 4
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 239000006014 omega-3 oil Substances 0.000 abstract description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 235000013311 vegetables Nutrition 0.000 abstract 1
- 238000001802 infusion Methods 0.000 description 40
- 230000000694 effects Effects 0.000 description 35
- 208000011580 syndromic disease Diseases 0.000 description 31
- 102000001399 Kallikrein Human genes 0.000 description 30
- 108060005987 Kallikrein Proteins 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 26
- 230000037396 body weight Effects 0.000 description 24
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 21
- 229940028435 intralipid Drugs 0.000 description 21
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 21
- 230000009467 reduction Effects 0.000 description 20
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 19
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 229960000187 tissue plasminogen activator Drugs 0.000 description 18
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
- 108010073385 Fibrin Proteins 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 108090000113 Plasma Kallikrein Proteins 0.000 description 14
- 229950003499 fibrin Drugs 0.000 description 14
- 235000021323 fish oil Nutrition 0.000 description 14
- 230000023597 hemostasis Effects 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 108010000499 Thromboplastin Proteins 0.000 description 11
- 102000002262 Thromboplastin Human genes 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 230000015271 coagulation Effects 0.000 description 11
- 238000005345 coagulation Methods 0.000 description 11
- 229960000984 tocofersolan Drugs 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 10
- 108010049003 Fibrinogen Proteins 0.000 description 9
- 102000008946 Fibrinogen Human genes 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 9
- 229940087168 alpha tocopherol Drugs 0.000 description 9
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 9
- 229940012952 fibrinogen Drugs 0.000 description 9
- 230000020764 fibrinolysis Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000002076 α-tocopherol Substances 0.000 description 9
- 235000004835 α-tocopherol Nutrition 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000282887 Suidae Species 0.000 description 8
- 235000021342 arachidonic acid Nutrition 0.000 description 8
- 229940114079 arachidonic acid Drugs 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 108010073651 fibrinmonomer Proteins 0.000 description 8
- 230000003480 fibrinolytic effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 230000008092 positive effect Effects 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 102000003827 Plasma Kallikrein Human genes 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000003820 Lipoxygenases Human genes 0.000 description 6
- 108090000128 Lipoxygenases Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 150000002066 eicosanoids Chemical class 0.000 description 6
- 230000002439 hemostatic effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002960 lipid emulsion Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 150000003595 thromboxanes Chemical class 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960001123 epoprostenol Drugs 0.000 description 5
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 206010073734 Microembolism Diseases 0.000 description 4
- 208000034486 Multi-organ failure Diseases 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 4
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 4
- 239000004019 antithrombin Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000008344 egg yolk phospholipid Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- -1 corticoid steroid Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940068998 egg yolk phospholipid Drugs 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000003024 amidolytic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 201000011475 meningoencephalitis Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229940037525 nasal preparations Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 150000003591 thromboxane A2 derivatives Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- RJHNVFKNIJQTQF-LMIBIYGPSA-N 2,3-Dinor-TXB2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CC(O)=O RJHNVFKNIJQTQF-LMIBIYGPSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940012193 contrave Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical class 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9200541A SE9200541D0 (sv) | 1992-02-24 | 1992-02-24 | New usee of omega-3-fatty acids |
| PCT/SE1993/000146 WO1993016691A1 (en) | 1992-02-24 | 1993-02-23 | New use of omega-3-fatty acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943102D0 NO943102D0 (no) | 1994-08-23 |
| NO943102L NO943102L (no) | 1994-10-21 |
| NO309704B1 true NO309704B1 (no) | 2001-03-19 |
Family
ID=20385410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943102A NO309704B1 (no) | 1992-02-24 | 1994-08-23 | Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5747533A (ja) |
| EP (1) | EP0627918B1 (ja) |
| JP (1) | JP3559280B2 (ja) |
| AT (1) | ATE207744T1 (ja) |
| AU (1) | AU671438B2 (ja) |
| CA (1) | CA2117535A1 (ja) |
| DE (1) | DE69331051T2 (ja) |
| DK (1) | DK0627918T3 (ja) |
| ES (1) | ES2162620T3 (ja) |
| NO (1) | NO309704B1 (ja) |
| SE (1) | SE9200541D0 (ja) |
| SG (1) | SG46238A1 (ja) |
| WO (1) | WO1993016691A1 (ja) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0987176A (ja) * | 1995-09-26 | 1997-03-31 | Shiseido Co Ltd | 糸球体腎炎抑制剤 |
| WO1998057628A1 (fr) * | 1997-06-16 | 1998-12-23 | Nippon Suisan Kaisha, Ltd. | Composition capable de supprimer le facteur de risque pendant l'exercice |
| EP0948963B1 (en) * | 1998-01-21 | 2003-05-07 | Fideline | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| US6054481A (en) * | 1998-01-21 | 2000-04-25 | Fideline | Pig appeasing pheromones for enhancing weight gain in a mammal |
| JP4754688B2 (ja) * | 1998-01-21 | 2011-08-24 | フィドゥラン | ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン |
| AU784123B2 (en) * | 1999-10-13 | 2006-02-09 | Marco A. Chacon | Therapeutic intervention to mimic the effect of caloric restriction |
| FR2804023B1 (fr) * | 2000-01-26 | 2002-09-20 | Johnson & Johnson Consumer Fr | Complement nutritionnel a base d'huile de pepins de cassis |
| JP2004527501A (ja) * | 2001-03-05 | 2004-09-09 | ピー． アーネスト，スティーヴン | 経腸処方 |
| US8729124B2 (en) * | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
| US7323206B1 (en) | 2003-03-04 | 2008-01-29 | B. Braun Medical Inc. | Reagents and methods for all-in-one total parenteral nutrition for neonates and infants |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036969A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Formation of barrier layer |
| WO2006036982A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| ZA200800251B (en) * | 2005-06-24 | 2009-04-29 | Drugrecure Aps | Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| JP2009525992A (ja) * | 2006-02-10 | 2009-07-16 | スポーツコム デンマーク アプス | コーティングを施した錠剤、その製造方法、及び関連する使用 |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| WO2008057328A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
| US20080207756A1 (en) * | 2007-02-27 | 2008-08-28 | Atrium Medical Corporation | Bio-absorbable oil suspension |
| CA2692394A1 (en) * | 2007-07-06 | 2009-01-15 | Seth J. Baum | Fatty acid compositions and methods of use |
| ES2748136T3 (es) | 2007-10-15 | 2020-03-13 | United Animal Health Inc | Método para aumentar el rendimiento de las crías |
| CA2704371A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| US20100323028A1 (en) * | 2007-11-30 | 2010-12-23 | Jbs United, Inc. | Method and composition for treating pulmonary hemorrhage |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
| US20110206741A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | DHA Triglyceride Emulsions |
| WO2011103512A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha free fatty acid emulsions |
| WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| US20210176999A1 (en) | 2011-04-17 | 2021-06-17 | Omega Foods, LLC | Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
| US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
| US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
| US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
| US10183044B2 (en) * | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
| US9655847B1 (en) * | 2016-07-18 | 2017-05-23 | National Guard Health Affairs | Therapeutic liposome and method of treating a subject having cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752618A (en) * | 1984-07-12 | 1988-06-21 | New England Deaconess Hospital | Method of minimizing efects of infection through diet |
| US4678808A (en) * | 1985-10-15 | 1987-07-07 | Baxter Travenol Laboratories, Inc. | Rapid acting intravenous emulsions of omega-3 fatty acid esters |
| WO1988001861A1 (en) * | 1986-09-17 | 1988-03-24 | Baxter Travenol Laboratories, Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases |
| DE3719097C1 (de) * | 1987-06-06 | 1988-06-09 | Fratzer Uwe | Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E |
| GB8729751D0 (en) * | 1987-12-21 | 1988-02-03 | Norsk Hydro As | Feed additive & feed containing such additive |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
-
1992
- 1992-02-24 SE SE9200541A patent/SE9200541D0/xx unknown
-
1993
- 1993-02-23 DK DK93905710T patent/DK0627918T3/da active
- 1993-02-23 AT AT93905710T patent/ATE207744T1/de active
- 1993-02-23 SG SG1996001422A patent/SG46238A1/en unknown
- 1993-02-23 WO PCT/SE1993/000146 patent/WO1993016691A1/en active IP Right Grant
- 1993-02-23 CA CA002117535A patent/CA2117535A1/en not_active Abandoned
- 1993-02-23 ES ES93905710T patent/ES2162620T3/es not_active Expired - Lifetime
- 1993-02-23 DE DE69331051T patent/DE69331051T2/de not_active Expired - Lifetime
- 1993-02-23 EP EP93905710A patent/EP0627918B1/en not_active Expired - Lifetime
- 1993-02-23 AU AU36529/93A patent/AU671438B2/en not_active Ceased
- 1993-02-23 US US08/290,905 patent/US5747533A/en not_active Expired - Lifetime
- 1993-02-23 JP JP51475493A patent/JP3559280B2/ja not_active Expired - Lifetime
-
1994
- 1994-08-23 NO NO943102A patent/NO309704B1/no not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/483,977 patent/US5731346A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2162620T3 (es) | 2002-01-01 |
| SG46238A1 (en) | 1998-02-20 |
| ATE207744T1 (de) | 2001-11-15 |
| SE9200541D0 (sv) | 1992-02-24 |
| EP0627918A1 (en) | 1994-12-14 |
| US5747533A (en) | 1998-05-05 |
| DE69331051D1 (de) | 2001-12-06 |
| JPH07507766A (ja) | 1995-08-31 |
| EP0627918B1 (en) | 2001-10-31 |
| AU3652993A (en) | 1993-09-13 |
| JP3559280B2 (ja) | 2004-08-25 |
| CA2117535A1 (en) | 1993-09-02 |
| DK0627918T3 (da) | 2002-01-14 |
| WO1993016691A1 (en) | 1993-09-02 |
| NO943102L (no) | 1994-10-21 |
| US5731346A (en) | 1998-03-24 |
| DE69331051T2 (de) | 2002-06-13 |
| AU671438B2 (en) | 1996-08-29 |
| NO943102D0 (no) | 1994-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309704B1 (no) | Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) | |
| Anez‐Bustillos et al. | Intravenous fat emulsion formulations for the adult and pediatric patient: understanding the differences | |
| Jain et al. | Omega-3 fatty acids and cardiovascular disease | |
| Vanschoonbeek et al. | Fish oil consumption and reduction of arterial disease | |
| Waitzberg et al. | New parenteral lipid emulsions for clinical use | |
| Hornstra | Dietary fats and arterial thrombosis | |
| DeCaterina et al. | Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. | |
| Mehta et al. | Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease: effects on indices of platelet and neutrophil function and exercise performance | |
| McCann et al. | Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. | |
| Matata et al. | Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide | |
| Carrel et al. | Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only | |
| US20070197644A1 (en) | Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| JPH08507531A (ja) | 進行性組織壊死、再潅流損傷、細菌転座及び成人呼吸困難症候群の予防法 | |
| McClaskey et al. | Subdural hematoma after a fall in an elderly patient taking high‐dose omega‐3 fatty acids with warfarin and aspirin: case report and review of the literature | |
| Owren | Coronary thrombosis: its mechanism and possible prevention by linolenic acid | |
| Mundi et al. | Emergence of mixed‐oil fat emulsions for use in parenteral nutrition | |
| Gong et al. | Aspirin enhances protective effect of fish oil against thrombosis and injury‐induced vascular remodelling | |
| Boisrame-Helms et al. | Lipid emulsions for parenteral nutrition in critical illness | |
| Kılıcoglu et al. | The ultrastructural research of liver in experimental obstructive jaundice and effect of honey | |
| Bayorh et al. | Effect of palm oil on blood pressure, endothelial function and oxidative stress | |
| Jeremy et al. | Cigarette smoking and cardiovascular disease | |
| Svaneborg et al. | The acute and short-time effect of supplementation with the combination of n− 3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids | |
| Hamazaki et al. | The safety of fish oils for those whose risk of injury is high | |
| Calder | Lipids and the critically ill patient | |
| Bilku et al. | Can enhanced recovery programmes be further improved by the addition of omega three fatty acids? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |